What intravenous dose of hydralazine is equivalent to a 25 mg oral dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IV to PO Hydralazine Dose Conversion

There is no established IV-to-PO dose conversion for hydralazine because NAT2 polymorphic acetylation affects oral but not intravenous pharmacokinetics, making direct dose equivalency impossible. 1

Why Direct Conversion Doesn't Exist

The fundamental pharmacokinetic difference between routes makes conversion problematic:

  • IV hydralazine bypasses first-pass metabolism entirely - no acetylation occurs before reaching systemic circulation 1
  • Oral hydralazine undergoes extensive first-pass hepatic metabolism via NAT2 acetylation, with bioavailability ranging from only 26-55% in healthy subjects 2 and as low as 9.9% in rapid acetylators with heart failure 3
  • Oral bioavailability varies dramatically based on NAT2 genotype (poor metabolizers have 2-3 times higher bioavailability than rapid metabolizers) 3

Practical Clinical Approach

Transitioning from IV to Oral Therapy

When converting from IV to oral hydralazine (which should occur within 24-48 hours per FDA labeling 4):

Start with standard oral dosing regimens rather than attempting mathematical conversion:

  • Initial oral dose: 40-75 mg total daily (divided into 2-4 doses) 1
  • For a patient previously on IV hydralazine 20-40 mg as needed, begin with 25 mg PO three to four times daily (total 75-100 mg/day)
  • Titrate based on blood pressure response, not the IV dose used

Key Dosing Parameters

FDA-approved oral dosing range: 4, 5

  • Minimum: 40 mg/day (10 mg four times daily)
  • Maximum: 300 mg/day (100 mg three times daily)
  • American Heart Association recommends limiting to 200 mg/day maximum to reduce drug-induced lupus risk 1

Standard IV dosing: 4

  • 20-40 mg per dose, repeated as necessary
  • Used only when oral administration impossible
  • Maximal BP decrease occurs 10-80 minutes post-injection

Critical Caveats

Route-Dependent Metabolism

Research demonstrates that oral administration produces relatively more of the acetylated metabolite MTP compared to IV administration (0.8-1.2% vs 1.4-2.3% urinary recovery), confirming route-dependent first-pass metabolism 2. This means the same milligram dose produces vastly different systemic drug exposure depending on route.

Dose-Dependent Bioavailability

At higher oral doses (225-3000 mg/day), bioavailability increases disproportionately due to saturation of first-pass metabolism 3. This nonlinear pharmacokinetics further complicates any conversion attempt.

Safety Considerations

  • IV hydralazine produces the most significant BP reduction among commonly used antihypertensives for severe inpatient hypertension (13 mmHg MAP reduction) 6
  • Risk of hypotension, acute kidney injury, and ICU transfers when IV agents used inappropriately for asymptomatic BP elevations 7, 8
  • Drug-induced lupus risk increases with cumulative exposure, particularly at doses ≥200 mg/day 1

Bottom Line

Rather than converting 25 mg PO to an IV equivalent, use standard IV dosing (20-40 mg) when IV route is necessary, and use standard oral starting doses (40-75 mg/day) when transitioning to oral therapy. Titrate each route independently based on clinical response, recognizing these are fundamentally different pharmacokinetic scenarios that cannot be mathematically equated.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.